Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer
Status:
Terminated
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The study will evaluate the efficacy and safety of sunitinib (Arm A), given at 37.5 mg orally
once daily, compared to sorafenib (Arm B), given orally at 400 mg twice daily, in patients
with inoperable liver cancer. A total number of 1200 patients will be enrolled, 600 on Arm A
and 600 on Arm B. Study treatment may be adjusted based on patient tolerance. and will be
given until disease progression, occurrence of unacceptable toxicity, or other withdrawal
criteria are met. After discontinuation of study treatment, patients will be followed up in
order to collect information on further antineoplastic therapy and survival.